Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02409680 · ClinicalTrials.gov registry record · NA
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)
A NA study, sponsored by NICHD Global Network for Women's and Children's Health.
- Completed
- Registry status
- NA
- Development phase
- 11,976
- Enrollment target
NCT02409680 is a NA study that has completed, run by NICHD Global Network for Women's and Children's Health. The registered enrollment target is 11,976 participants.
The verdict
NCT02409680, a NA study, has completed, sponsored by NICHD Global Network for Women's and Children's Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 11,976 participants
- Enrollment target
Study Summary
Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary outcome. Such a clinical trial in a racially, ethnically and geographically diverse population could best be accomplished by the established infrastructure of the Global Network for Women's and Children's Health Research (GN).
Interventions
- DRUG Placebo
- DRUG Low dose aspirin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,976 participants |
| Start Date | 2016-03-23 |
| Est. Completion | 2019-04-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02409680
The ClinicalTrials.gov registry entry for NCT02409680 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 11,976 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Global Network for Women's and Children's Health, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02409680 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02409680 about?
NCT02409680 is a clinical study titled "Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)". Available data suggest that low dose aspirin may be a safe, widely available and inexpensive intervention that may significantly reduce the risk of preterm birth. However, this possibility needs to be proven in a properly designed randomized controlled trial (RCT) with preterm birth as the primary o...
What is the current status of trial NCT02409680?
This trial is currently completed. It is a NA study. The enrollment target is 11,976 participants. The study started on 2016-03-23. Estimated completion is 2019-04-11.
What interventions are being tested in trial NCT02409680?
The interventions under investigation include: Placebo (DRUG), Low dose aspirin (DRUG).
Who is sponsoring clinical trial NCT02409680?
This trial is sponsored by NICHD Global Network for Women's and Children's Health, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.